RAFAEL HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
RAFAEL HOLDINGS, INC. (RFL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 24.56 thousand shares for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-04-30 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-01-31 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-10-31 was 24.56K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-07-31 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 395.00K shares, a 58.00% increase from fiscal 2024.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 250.00K shares, a 42.86% increase from fiscal 2023.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 175.00K shares, a 66.24% decline from fiscal 2022.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 518.30K shares, a 337.72% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | 0.00 shares derived: sum of 2 quarters · filed 2026-06-11 | 24.56K shares 10-Q · filed 2026-06-11 | 24.56K shares derived: sum of 4 quarters · filed 2026-06-11 |
| 2026-01-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | 24.56K shares 10-Q · filed 2026-03-16 | 24.56K shares derived: sum of 3 quarters · filed 2026-03-16 | |
| 2025-10-31 | 24.56K shares 10-Q · filed 2025-12-12 | 24.56K shares derived: sum of 2 quarters · filed 2025-12-12 | ||
| 2025-07-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | 395.00K shares 10-K · filed 2025-10-29 | ||
| 2025-04-30 | 395.00K shares 10-Q · filed 2025-06-11 | |||
| 2024-07-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | 0.00 shares derived: sum of 2 quarters · filed 2024-12-20 | 250.00K shares 10-K/A · filed 2024-12-20 | |
| 2024-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | 250.00K shares 10-Q · filed 2024-06-14 | ||
| 2024-01-31 | 250.00K shares 10-Q · filed 2024-03-14 | |||
| 2023-07-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | 25.00K shares derived: sum of 2 quarters · filed 2024-12-20 | 175.00K shares 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | 25.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | 175.00K shares 10-Q · filed 2023-06-13 | ||
| 2023-01-31 | 150.00K shares 10-Q · filed 2023-03-14 | |||
| 2022-07-31 | 518.30K shares 10-K · filed 2023-10-30 | |||
| 2021-10-31 | 98.00M shares 10-Q/A · filed 2022-02-28 | |||
| 2021-07-31 | 118.41K shares 10-K · filed 2022-10-31 | |||
| 2021-04-30 | 118.41K shares 10-Q · filed 2021-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |